Cargando…
Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas
Epigenetic mechanisms, such as DNA methylation and histone modifications (e.g., acetylation and deacetylation), are strongly implicated in the carcinogenesis of various malignancies. During transcription, the expression and functionality of coding gene products are altered following the histone acet...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tech Science Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207982/ https://www.ncbi.nlm.nih.gov/pubmed/37305348 http://dx.doi.org/10.32604/or.2022.026913 |
_version_ | 1785046571786698752 |
---|---|
author | MANTA, ASPASIA KAZANAS, SPYRIDON KARAMAROUDIS, STEFANOS GOGAS, HELEN ZIOGAS, DIMITRIOS C. |
author_facet | MANTA, ASPASIA KAZANAS, SPYRIDON KARAMAROUDIS, STEFANOS GOGAS, HELEN ZIOGAS, DIMITRIOS C. |
author_sort | MANTA, ASPASIA |
collection | PubMed |
description | Epigenetic mechanisms, such as DNA methylation and histone modifications (e.g., acetylation and deacetylation), are strongly implicated in the carcinogenesis of various malignancies. During transcription, the expression and functionality of coding gene products are altered following the histone acetylation and deacetylation. These processes are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. HDAC inhibitors (HDACis) have been developed as promising therapeutic agents, to limit exposure to traditional and toxic chemotherapies and offer more alternatives for some specific malignant diseases with limited options. Mechanistically, these agents affect many intracellular pathways, including cell cycle arrest, apoptosis and differentiation, and their mechanism of action mainly depends on the type of cancer. Currently, five HDACis have been approved for the treatment of several hematological malignancies (e.g., T-cell lymphoma subtypes and multiple myeloma); while, many of them are tested for further therapeutic indications in solid tumors (e.g., colorectal, thyroid, breast, lung and pancreatic cancer). Herein, we review the literature and gather all available evidence, from in vitro and in vivo data to clinical trial results, that recognizes the antitumor activity of HDACis on pheochromocytomas and paragangliomas; and supports their clinical implementation in the treatment of these rare neuroendocrine tumors at metastatic setting. |
format | Online Article Text |
id | pubmed-10207982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Tech Science Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102079822023-06-10 Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas MANTA, ASPASIA KAZANAS, SPYRIDON KARAMAROUDIS, STEFANOS GOGAS, HELEN ZIOGAS, DIMITRIOS C. Oncol Res Review Epigenetic mechanisms, such as DNA methylation and histone modifications (e.g., acetylation and deacetylation), are strongly implicated in the carcinogenesis of various malignancies. During transcription, the expression and functionality of coding gene products are altered following the histone acetylation and deacetylation. These processes are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. HDAC inhibitors (HDACis) have been developed as promising therapeutic agents, to limit exposure to traditional and toxic chemotherapies and offer more alternatives for some specific malignant diseases with limited options. Mechanistically, these agents affect many intracellular pathways, including cell cycle arrest, apoptosis and differentiation, and their mechanism of action mainly depends on the type of cancer. Currently, five HDACis have been approved for the treatment of several hematological malignancies (e.g., T-cell lymphoma subtypes and multiple myeloma); while, many of them are tested for further therapeutic indications in solid tumors (e.g., colorectal, thyroid, breast, lung and pancreatic cancer). Herein, we review the literature and gather all available evidence, from in vitro and in vivo data to clinical trial results, that recognizes the antitumor activity of HDACis on pheochromocytomas and paragangliomas; and supports their clinical implementation in the treatment of these rare neuroendocrine tumors at metastatic setting. Tech Science Press 2023-02-03 /pmc/articles/PMC10207982/ /pubmed/37305348 http://dx.doi.org/10.32604/or.2022.026913 Text en © 2022 Manta et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review MANTA, ASPASIA KAZANAS, SPYRIDON KARAMAROUDIS, STEFANOS GOGAS, HELEN ZIOGAS, DIMITRIOS C. Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas |
title | Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas |
title_full | Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas |
title_fullStr | Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas |
title_full_unstemmed | Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas |
title_short | Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas |
title_sort | histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207982/ https://www.ncbi.nlm.nih.gov/pubmed/37305348 http://dx.doi.org/10.32604/or.2022.026913 |
work_keys_str_mv | AT mantaaspasia histonedeacetylaseinhibitorsasanoveltherapeuticapproachforpheochromocytomasandparagangliomas AT kazanasspyridon histonedeacetylaseinhibitorsasanoveltherapeuticapproachforpheochromocytomasandparagangliomas AT karamaroudisstefanos histonedeacetylaseinhibitorsasanoveltherapeuticapproachforpheochromocytomasandparagangliomas AT gogashelen histonedeacetylaseinhibitorsasanoveltherapeuticapproachforpheochromocytomasandparagangliomas AT ziogasdimitriosc histonedeacetylaseinhibitorsasanoveltherapeuticapproachforpheochromocytomasandparagangliomas |